72例男性乳腺癌患者临床病理特征和预后分析  

Analysis of Clinicopathologic Characteristics and Prognosis of 72 Chinese Male Patients with Breast Cancer

作　　者：周菲菲[1] 夏良平[1] 王曦[2] 郭桂芳[2] 戎煜明[2] 丘惠娟[2] 张蓓[2] 

机构地区：[1]华南肿瘤学国家重点实验室,中山大学肿瘤防治中心综合科,广州市510060 [2]华南肿瘤学国家重点实验室,中山大学肿瘤防治中心乳腺科,广州市510060

出　　处：《中国肿瘤临床》2010年第22期1296-1299,共4页Chinese Journal of Clinical Oncology

摘　　要：目的:男性乳腺癌较少见,并且其特征在全球东西方患者之间也有差异。本研究旨在基于相对比较大的样本基础上提供更为可靠的男性乳腺癌的临床病理特征及预后信息。方法:收集1969年1月至2009年3月在中山大学附属肿瘤医院经病理确诊、随访资料齐全的72例男性乳腺癌患者的临床资料,回顾性分析男性乳腺癌临床病理特征、局部复发率、远处转移率和5年生存率。结果:1)浸润性导管癌占81.9%;ER、PR、HER-2阳性率分别为90.9%,84.8%,3.3%。2)98.5%患者以乳腺肿物为首发症状,69.8%肿物位于乳晕区。3)67.6%患者接受根治术,22.1%接受改良根治术;50.0%接受术后辅助化疗,15.3%接受新辅助化疗;19.4%接受术后放疗;44.4%患者接受内分泌治疗。4)5年总生存率为72.4%,其中Ⅰ期100%、Ⅱ期74.2%、Ⅲ期57.2%、Ⅳ期0%。5)各有12.5%患者出现局部复发和远处转移,发生局部复发和转移的中位时间分别为12个月和14个月。结论:中国男性乳腺癌以无痛性乳晕区肿块为常见首发症状,以浸润性导管癌最常见,ER、PR阳性率高而HER-2阳性率低,治疗以手术为主的包括化疗、放疗、内分泌治疗的综合治疗,预后比较好。Objective： The characteristics of male breast cancer （MBC）, which is a rare disease, are different between Western and Eastern people. Up until now almost all the information about Chinese MBC has been based on small samples. The aim of this study is to explore the characteristics of Chinese MBC based on a relatively larger sample. Methods： Clinical data of 72 patients with MBC, who were histopathologically confirmed and treated at the Cancer Center of Sun Yat-sen University between January 1969 and March 2009, were collected. The clinicopathologic features, Iocoregional recurrence rate, metastatic rate, and 5-year survival rate were retrospectively analyzed. Results： Infiltrating ductal carcinoma was the predominant pathological subtype, accounting for 81.9%. The positive rates of ER, PR, and HER-2 were 90.9%, 84.8%, and 3.3%, respectively. Mass in the breast was the major initial sign in 98.5% patients and was mainly located in the areola area, accounting for 69.8%. About 67.6% patients received radical mastectomy, 22.1% received modified radical mastectomy; 50% received adjuvant chemotherapy, 15.3% received neoadjuvant therapy; 19.4% patients received adjuvant radiotherapy, and 44.4% received endocrine therapy. The 5-year overall survival rate of the whole group was 72.4%. The 5-year overall survival rates for stage Ⅰ,Ⅱ,Ⅲ and Ⅳwere 100%, 74.2%, 57.2%, and 0, respectively. About 12.5% of patients suffered Iocoregional recurrence at 12 months, and 12.5% of patients had distant metastasis at 14 months. Conclusion： The characteristics of Chinese MBC include a predominant pathological subtype of infiltrating ductal carcinoma, higher expression rate of ER and PR and lower expression rate of HER-2. Comprehensive treatment with primary surgery integrated with chemotherapy, radiotherapy or endocrine therapy provides a better prognosis.

关 键 词：男性乳腺癌 病理特点 临床特征 生存率 复发率 

分 类 号：R737.9[医药卫生—肿瘤]